Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator

1. A method of evaluating a drug for improving or treating cellulite, comprising the steps of:

harvesting dermal fibroblast cells from human skin tissue by microdissection and culturing the dermal fibroblast cells;

adding a candidate drug to the cultured dermal fibroblast cells;

determining an expression level of fibulin-3 in the cultured dermal fibroblast cells after adding the candidate drug by quantitative PCR;

comparing a control expression level of fibulin-3 with the determined expression level of fibulin-3 after adding the candidate drug; and

determining that the candidate drug has a cellulite-suppressing activity when the determined expression level of fibulin-3 is enhanced compared to the control expression level of fibulin-3.

2. The method according to claim 1 , wherein the determination that the candidate drug has a cellulite-suppressing activity requires that the determined expression of fibulin-3 is enhanced by 20% or more compared to the control expression level of fibulin-3.

3. The method of claim 2 , wherein the enhancement is 35% or more.

4. The method of claim 2 , wherein the enhancement is 50% or more.

5. The method of claim 1 , wherein the quantitative PCR uses a primer selected from the group consisting of SEQ ID NOs: 5 and 6.

6. A method for screening a drug which has an activity for improving or treating cellulite, the method comprising:

extracting dermal fibroblast cells from human skin tissue by microdissection and culturing the dermal fibroblast cells;

providing a test sample of the cultured dermal fibroblast cells and a control sample;

adding a candidate drug to the test sample of cultured dermal fibroblast cells;

determining an expression level of fibulin-3 in each of a) the test sample after adding the candidate drug and b) the control sample by quantitative PCR;

comparing the expression level of fibulin-3 determined in the control sample with the expression level of fibulin-3 determined in the test sample; and

determining that the candidate drug has an activity for improving or treating cellulite when the expression level of fibulin-3 is increased in the test sample compared to the expression level of fibulin-3 in the control sample.

7. The method according to claim 6 , wherein the determination that the candidate drug has an activity for improving or treating cellulite requires that the expression level of fibulin-3 in the test sample is enhanced by 20% or more compared to the expression level of fibulin-3 in the control sample.

8. The method of claim 7 , wherein the enhancement is 35% or more.

9. The method of claim 7 , wherein the enhancement is 50% or more.

10. The method of claim 6 , wherein the quantitative PCR uses a primer selected from the group consisting of SEQ ID NOs: 5 and 6.